)
)
UCB Investor Relations Material
Latest events
H1 2024
UCB
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from UCB SA
Access all reports
UCB SA is a global biopharmaceutical company specializing in the discovery and development of innovative medicines and solutions for severe neurological and immunological disorders. The company's main areas of focus include treatments for conditions such as epilepsy, Parkinson's disease, and various immunological diseases. UCB operates through its biopharmaceutical segment, which develops, manufactures, and markets these therapies. The company is headquartered in Brussels, Belgium, and its shares are listed on the Euronext Brussels.
Key slides for UCB SA
H1 2024
UCB SA
CMD 2024 Presentation
UCB SA
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
UCB
Country
🇧🇪 Belgium